Neo Ivy Capital Management Has $2.36 Million Stock Position in IQVIA Holdings Inc. $IQV

Neo Ivy Capital Management lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1,065.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,436 shares of the medical research company’s stock after purchasing an additional 11,369 shares during the period. Neo Ivy Capital Management’s holdings in IQVIA were worth $2,362,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Artisan Partners Limited Partnership acquired a new position in IQVIA during the second quarter worth $515,772,000. Norges Bank acquired a new stake in IQVIA in the second quarter valued at $270,160,000. AQR Capital Management LLC grew its position in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after acquiring an additional 879,701 shares during the period. Laurel Wealth Advisors LLC increased its stake in shares of IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after purchasing an additional 774,681 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after purchasing an additional 581,157 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 2.2%

IQVIA stock opened at $174.56 on Friday. The company’s 50-day moving average price is $207.22 and its two-hundred day moving average price is $207.37. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market cap of $29.62 billion, a P/E ratio of 22.21, a P/E/G ratio of 1.72 and a beta of 1.39. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on IQV shares. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a research note on Friday, February 6th. Morgan Stanley set a $240.00 price objective on IQVIA in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Stifel Nicolaus reduced their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Finally, Evercore restated an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $231.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.